# Open Label, Multicenter, Randomized, Controlled Study of IM or Oral Exemestane (Aromasin) in Postmenopausal Women

> **NCT00040014** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 100 (—)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** exemestane

## Key facts

- **NCT ID:** NCT00040014
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2002-06
- **Primary completion:** 2006-12
- **Final completion:** 2006-12
- **Target enrollment:** 100 (—)
- **Last updated:** 2012-02-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00040014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00040014, "Open Label, Multicenter, Randomized, Controlled Study of IM or Oral Exemestane (Aromasin) in Postmenopausal Women". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00040014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*